Association of circulating matrix metalloproteinases with carotid artery characteristics: The atherosclerosis risk in communities carotid mri study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 5, 2010, Pages 1034-1042

  Gaubatz, John W ^a   Ballantyne, Christie M ^a   Wasserman, Bruce A ^b   He, Max ^c   Chambless, Lloyd E ^c   Boerwinkle, Eric ^d   Hoogeveen, Ron C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d NONE

Author keywords

Atherosclerosis; Carotid; IMT; Luminex; MMP; MRI; Multianalyte profiling; TIMP 1

Indexed keywords

CALCIUM; GADODIAMIDE; GADOLINIUM; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LIPID; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; COHORT ANALYSIS; COMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOM SAMPLE; RISK;

AGED; BIOLOGICAL MARKERS; CALCINOSIS; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FIBROSIS; HUMANS; LIPIDS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77951497077     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.195370     Document Type: Article

References (35)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97:1095-1102.
3. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90: 251-262.
4. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21494.
5. Keeling WB, Armstrong PA, Stone PA, Bandyk DF, Shames ML. An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vasc Endovascular Surg. 2005;39: 457-464.
6. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases and atherosclerosis: therapeutic aspects. Ann Biol Clin. 2003;61:147-158.
7. Rouis M, Adamy C, Duverger N, Lesnik P, Horellou P, Moreau M, Emmanuel F, Caillaud JM, Laplaud PM, Dachet C, Chapman MJ. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation. 1999;100:533-540.
8. Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, Vick GW III, Karmonik C, Via DP, Morrisett JD. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarter-ectomy tissues. Arterioscler Thromb Vasc Biol. 2006;26:2351-2358.
9. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
10. Kai HK, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
11. Noji Y, Kajinami K, Kawashiri M, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380-384.
12. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129: 687-702.
13. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49: 223-233.
14. Wasserman BA, Smith WI, Trout HH, Cannon RO, Balaban RS, Arai AE. Carotid artery atherosclerosis: in vivo morphologic characterization with gadolinium-enhanced double-oblique MR imaging: initial results. Radiology. 2002;223:566-573.
15. Wagenknecht L, Wasserman B, Chambless L, Coresh J, Folsom A, Mosley T, Ballantyne C, Sharrett R, Boerwinkle E. Correlates of carotid plaque presence and composition as measured by MRI: the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Imaging. 2009;2: 314-322.
16. Saam T, Yuan C, Chu B, Takaya N, Underhill H, Cai J, Tran N, Polissar NL, Neradilek B, Jarvik GP, Isaac C, Garden GA, Maravilla KR, Hashimoto B, Hatsukami TS. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis. 2007;194:e34-e42. (Pubitemid 47513067)
17. Zhao X, Miller ZE, Yuan C. Atherosclerotic plaque imaging by carotid MRI. Curr Cardiol Rep. 2009;11:70-77.
18. Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, McClure CD, Finklea L, Spinale FG, Zile MR. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail. 2007;13:530-540.
19. Samnegard A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J, McPheat W, Tornvall P, Bergstrand L, Ericsson CG, Hamsten A, Eriksson P. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myo-cardial infarction. J Intern Med. 2005;258:411-419.
20. Luan ZX, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-775.
21. Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, Shin EK. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol. 2003;88:77-82.
22. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2008;28:2108-2114.
23. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235-239.
24. Thrailkill KM, Moreau CS, Cockrell G, Simpson P, Goel R, North P, Fowlkes JL, Bunn RC. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology. Clin Chem Lab Med. 2005;43:1392-1399.
25. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
26. Doherty TM, Detrano RC, Mautner SL, Mautner GC, Shavelle RM. Coronary calcium: the good, the bad, and the uncertain. Am Heart J. 1999;137:806-814.
27. Miralles M, Merino J, Busto M, Perich X, Barranco C, Vidal-Barraquer F. Quantification and characterization of carotid calcium with multi-detector CT-angiography. Eur J Vasc Endovasc Surg. 2006;32:561-567.
28. Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun. 2004;324:440-445.
29. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J. 2006;151:1101.e1-1101.e8.
30. Beaudeux JL, Giral P, Bruckert E, Bernard M, Foglietti MJ, Chapman MJ. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis. 2003;169:139-146.
31. Nambi V, Morrison AC, Hoogeveen RC, Coresh J, Miles S, Rhodes CE, Sharrett AR, Boerwinkle BE, Ballantyne CM. Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Tex Heart Inst J. 2008;35:388-394.
32. Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Cresti S, Cavallaro A. Metalloproteinases and their inhibitors are markers of plaque instability. Surgery. 2005;137:355-363.
33. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest. 2003;33:648-656.
34. Rossignol P, Cambillau M, Bissery A, Mouradian D, Benetos A, Michel JB, Plouin PF, Chatellier G, Jacob MP. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors. Clin Exp Pharmacol Physiol. 2008;35:464-469.
35. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem. 2007;40: 119-123.